Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T14:55:48.701Z.
Calculation as of: 2026-10-06T14:55:48.701Z.
Quote observation: 2026-10-06T14:55:27.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 236ecad6846b0cc00793ea2ceb9f38c60eee5e96b58175726d9ae7432cdeb63e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$665.40M
Price/FCF Ratio
16.40
TTM Avg
12.94
3Y Avg
32.63
5Y Avg
32.63
Market Cap
$692.29M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$666.36M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$707.95M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$708.19M
Price/FCF Ratio
2.16
TTM Avg
4.81
3Y Avg
5.21
5Y Avg
6.10
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Annexon, Inc. (ANNX) | $676.72M | N/A | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $704.02M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $665.40M | 16.40 | 12.94 | 32.63 | 32.63 |
| Anteris Technologies Global Corp. (AVR)vs › | $692.29M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $666.95M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $666.36M | N/A | N/A | N/A | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $707.95M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $708.19M | 2.16 | 4.81 | 5.21 | 6.10 |
| OmniAb, Inc. (OABI)vs › | $643.45M | N/A | 697.87 | 748.88 | 748.88 |
| Aura Biosciences, Inc. (AURA)vs › | $635.69M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
